A Tumor-Agnostic NTRK (TRK) Inhibitor

Cell. 2019 Mar 21;177(1):8. doi: 10.1016/j.cell.2019.02.049.

Abstract

Larotrectinib is a small-molecule kinase inhibitor that targets NTRK fusions that occur in multiple types of cancer. Its FDA approval represents the first instance of a treatment indication being designated "tumor-agnostic" from the outset, being based on actionable genomic insights. To view this Bench to Bedside, open or download the PDF.

Publication types

  • Review

MeSH terms

  • Humans
  • Neoplasms / genetics
  • Oncogene Proteins, Fusion / genetics
  • Protein Kinase Inhibitors / metabolism
  • Pyrazoles / metabolism*
  • Pyrazoles / pharmacology*
  • Pyrimidines / metabolism*
  • Pyrimidines / pharmacology*
  • Receptor Protein-Tyrosine Kinases / metabolism
  • Receptor Tyrosine Kinase-like Orphan Receptors / agonists
  • Receptor Tyrosine Kinase-like Orphan Receptors / metabolism*
  • Receptor, trkB / metabolism

Substances

  • Oncogene Proteins, Fusion
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • Receptor Protein-Tyrosine Kinases
  • Receptor Tyrosine Kinase-like Orphan Receptors
  • Receptor, trkB
  • larotrectinib